Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
Steady: 0 in the last 7 days
Updated oct 16
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.Sub-event
Omeros submitted BLA for narsoplimab approval to the FDA.1 source
Keep exploring
The entities involved
-
Omeros Corporation
company in Seattle, United States
Nothing else this week.
- FDA
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Cronus Pharma LLC, headquartered in East Brunswick, is launching products in the U.S. market and seeking FDA approval.
- FDA approval supports NDA submission in Aurora.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
Coverage
Newest first; wire copies grouped- Business WireOmeros Corporation Reports Second Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, August 14, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced r
- ACCESS NewswireD. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering NEW YORK CITY, NEW YORK / ACCESS Newswire / July
- Unknown outlet
- Unknown outlet